Abstract Number: 126 • 2023 Pediatric Rheumatology Symposium
Facilitating Peer-to-Peer Conversations Around Key Clinical Trial Recruitment Barriers in the Limit-JIA Trial Using Low-Fidelity Video Capture
Background/Purpose: The LIMIT-JIA trial aims to study if early abatacept treatment can prevent disease extension in children with recent-onset, uncomplicated, and oligoarticular or limited JIA.…Abstract Number: 109 • 2023 Pediatric Rheumatology Symposium
Long-term Safety of Biologics versus Conventional Synthetic Treatments in Systemic Juvenile Idiopathic Arthritis Patients
Background/Purpose: The better understanding of systemic Juvenile Idiopathic Arthritis (sJIA) pathogenesis and availability of new drugs, such as biologic disease-modifying anti-rheumatic drugs (bDMARDs) specifically dedicated…Abstract Number: 117 • 2023 Pediatric Rheumatology Symposium
A Descriptive Study of Patients with Multisystem Inflammatory Syndrome in Children
Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…Abstract Number: 130 • 2023 Pediatric Rheumatology Symposium
Levels of Neutrophil Extracellular Traps Correlate with Disease Activity in Pediatric Lupus
Background/Purpose: Pediatric lupus (pSLE) is a multisystemic autoimmune disease characterized by autoantibody production leading to organ damage. Neutrophil extracellular traps (NETs) are considered a potential…Abstract Number: 106 • 2023 Pediatric Rheumatology Symposium
Caregivers’ Perspectives on Barriers to Care in Juvenile Localized and Systemic Scleroderma
Background/Purpose: Juvenile localized scleroderma (LS) and systemic sclerosis (SSc) are rare rheumatic diseases often associated with severe morbidities. Delays in diagnosis are common, putting children…Abstract Number: 107 • 2023 Pediatric Rheumatology Symposium
Validation of Serious Adverse Event Reporting in a Multicenter Registry
Background/Purpose: Children with rheumatic disease frequently require management with immune suppressing medications. The benefits of these interventions often outweigh the risks, however serious adverse events…Abstract Number: 113 • 2023 Pediatric Rheumatology Symposium
Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (sJIA) is a pediatric autoinflammatory condition, known for significant variability between patients in its severity and long-term outcomes. The classification…Abstract Number: 099 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Juvenile Dermatomyositis
Background/Purpose: Juvenile Dermatomyositis (JDM) is theorized to occur in a genetically susceptible individual as a response to an environmental trigger, leading to autoimmunity and inflammation.…Abstract Number: 114 • 2023 Pediatric Rheumatology Symposium
Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort
Background/Purpose: Anti-nuclear antibodies (ANA) are important in the diagnosis of Systemic Lupus Erythematosus (SLE). Of the disease specific ANAs, anti-dsDNA and anti- Smith antibodies carry…Abstract Number: 100 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): II – A Longitudinal Assessment of Muscle Strength by Manual Muscle Test (MMT) and Childhood Myositis Assessment Scale (CMAS) Tools
Background/Purpose: Muscle weakness is often progressive and persistent in Juvenile Dermatomyositis (JDM). Muscle strength testing is useful for evaluating severity of muscle weakness. There is…Abstract Number: 108 • 2023 Pediatric Rheumatology Symposium
Development of Mental Health Guidance Statements for Pediatric Rheumatology
Background/Purpose: There are high rates of anxiety and depression in youth with rheumatologic diseases, with known impact on health-related outcomes. Thus, it is important to…Abstract Number: 098 • 2023 Pediatric Rheumatology Symposium
Characterization of Pulmonary Nodules in Juvenile-onset Systemic Sclerosis: A Single Center Case-Series
Background/Purpose: Given the high prevalence of intestinal lung disease (ILD) in systemic sclerosis (SSc) and the low sensitivity of pulmonary function testing for diagnosing ILD,…Abstract Number: 095 • 2023 Pediatric Rheumatology Symposium
Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe
Background/Purpose: Chronic parenchymal lung disease (LD) is a new emerging severe life-threatening complication of sJIA. The number of sJIA patients with LD is apparently increasing…Abstract Number: 101 • 2023 Pediatric Rheumatology Symposium
Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have…Abstract Number: 103 • 2023 Pediatric Rheumatology Symposium
Clinical, Serologic, and Imaging Findings of Rhupus Syndrome in the Pediatric Population: A Systematic Literature Review
Background/Purpose: Pediatric Rhupus syndrome is a complex autoimmune disease characterized by overlapping clinical and immunological features of Juvenile Idiopathic Arthritis (JIA) and juvenile Systemic Lupus…
- « Previous Page
- 1
- …
- 546
- 547
- 548
- 549
- 550
- …
- 2607
- Next Page »
